ZVRA Stock Price, Chart, Stats & News
Zevra Therapeutics, Inc. (ZVRA) does not currently pay a dividend.
ZVRA chart
Fundamentals
Gross margin | 84.22% |
Operating margin | -59.12% |
Pretax margin | 81.41% |
Net margin | 78.17% |
Effective tax rate | 3.98% |
ROA | 29.23% |
ROE | 74.63% |
D/E | 0.41x |
Interest coverage ratio | -7.89x |
ZVRA valuation
P/E | 4.38x |
P/S | 5.05x |
P/B | 3.28x |
P/CF | -317.05x |
P/FCF | -221.04x |
P/OCF | -317.05x |
PEG | 0.04x |
EV multiple | 5.44x |
About
Zevra Therapeutics, Inc., founded in 2006 and based in Celebration, Florida, is a biopharmaceutical company dedicated to discovering and developing innovative treatments for rare diseases. The company employs its proprietary Ligand Activated Therapy (LAT) technology to create novel prodrug versions of existing FDA-approved medications or to enable new applications for other compounds, primarily addressing serious medical conditions within the United States. Zevra's development pipeline is strategically concentrated on high-unmet-need therapeutic areas, including attention deficit hyperactivity disorder (ADHD), stimulant use disorder, and various rare central nervous system (CNS) conditions, such as idiopathic hypersomnia (IH).
Similar securities
Based on sector and market capitalization
